HGF, is a ligand for the receptor tyrosine kinase c-Met. HGF/c-Met signaling promotes cell proliferation, survival, migration, and invasion. By neutralizing HGF, rilotumumab aims to suppress tumor progression and metastasis, particularly in cancers with dysregulated c-Met pathway activity.